Update: this study is closed to enrollment.
The Weill Cornell Lymphoma Program is now enrolling people in a new clinical trial for patients with peripheral T-cell lymphoma, a type of non-Hodgkin lymphoma that generally has a poor outcome with conventional chemotherapy.
The purpose of this study is to determine the effect of the experimental drug MLN8237 on patients with relapsed or refractory peripheral T-cell lymphoma. MLN8237 is an Aurora Kinase A inhibitor that has been developed to interfere with cell division, which is required for cancer to grow. It has been shown to have anti-cancer activity in laboratory studies as well as in patients who have non-Hodgkin lymphoma including peripheral T-cell lymphoma in earlier phase I/II studies.
MLN8237 is available as a tablet. Patients will take MLN8237 on Days 1-7, twice a day with 8 ounces of water. Patients will continue with this treatment every 3 weeks for up to a year as long as their disease does not get worse. Whether patients remain on study treatment or not, the study physician will follow their health status for a maximum of 2 years from study enrollment.
- Relapsed/refractory peripheral T-cell non-Hodgkin lymphoma
- Must have received at least one course of prior systemic therapy which may include chemotherapy, antibody therapy or immunotherapy
- May have received prior radiation in combination with systemic therapy
- Must not have received a previous allogeneic stem cell transplant or be within 90 days of autologous stem cell transplant
- Detailed eligibility reviewed when you contact the study team
For more information about the study, call June Greenberg, RN at (212) 746-2651 or email June at email@example.com.
The physician leading the study at Weill Cornell is Dr. Jia Ruan. Click here to read Dr. Ruan’s clinical and research profile.
Click here to view all current lymphoma clinical trials at Weill Cornell Medical College.